Yesterday, Oct. 5, 2015, 61 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $92.16 to $1,249,965.40.

Highlighted Stocks Traded by Insiders:

Willamette Valley Vineyards (WVVI) - FREE Research Report

Ellis James L, who is Director at Willamette Valley Vineyards, sold 1,147 shares at $6.79 on Oct. 5, 2015. Following this transaction, the Director owned 42,578 shares meaning that the stake was reduced by 2.62% with the 1,147-share transaction.

Smith Craig Alan, who is Director at Willamette Valley Vineyards, bought 1,205 shares at $4.15 on Oct. 5, 2015. Following this transaction, the Director owned 1,205 shares meaning that the stake was boosted by 100% with the 1,205-share transaction.

The shares most recently traded at $6.85, up $2.70, or 39.42% since the insider transaction. Historical insider transactions for Willamette Valley Vineyards go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 4,275
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 5,275
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 5,275

The average volume for Willamette Valley Vineyards has been 12,700 shares per day over the past 30 days. Willamette Valley Vineyards has a market cap of $33.5 million and is part of the consumer goods sector and food & beverage industry. Shares are up 17.41% year-to-date as of the close of trading on Monday.

Willamette Valley Vineyards, Inc. produces and sells wines in the United States and internationally. The company has a P/E ratio of 14.6.

Exclusive Offer: Get the latest Stock Analysis on WVVI - FREE

TheStreet Quant Ratings

rates Willamette Valley Vineyards as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Willamette Valley Vineyards Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cantel Medical (CMN) - FREE Research Report

Berman Ann E, who is Director at Cantel Medical, sold 2,462 shares at $56.67 on Oct. 5, 2015. Following this transaction, the Director owned 6,130 shares meaning that the stake was reduced by 28.65% with the 2,462-share transaction.

The shares most recently traded at $54.78, down $1.89, or 3.45% since the insider transaction. Historical insider transactions for Cantel Medical go as follows:

  • 4-Week # shares sold: 37,415
  • 12-Week # shares sold: 37,415
  • 24-Week # shares sold: 77,361

The average volume for Cantel Medical has been 123,800 shares per day over the past 30 days. Cantel Medical has a market cap of $2.3 billion and is part of the health care sector and health services industry. Shares are up 27.81% year-to-date as of the close of trading on Monday.

Cantel Medical Corp. provides infection prevention and control products and services in the healthcare market. The stock currently has a dividend yield of 0.18%. The company has a P/E ratio of 48.8. Currently, there is 1 analyst who rates Cantel Medical a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMN - FREE

TheStreet Quant Ratings

rates Cantel Medical as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Cantel Medical Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NuVasive (NUVA) - FREE Research Report

Miles Patrick, who is President and COO at NuVasive, sold 15,000 shares at $48.10 on Oct. 5, 2015. Following this transaction, the President and COO owned 47,627 shares meaning that the stake was reduced by 23.95% with the 15,000-share transaction.

The shares most recently traded at $54.78, up $6.68, or 12.19% since the insider transaction. Historical insider transactions for NuVasive go as follows:

  • 4-Week # shares sold: 5,806
  • 12-Week # shares sold: 66,182
  • 24-Week # shares sold: 87,549

The average volume for NuVasive has been 493,400 shares per day over the past 30 days. NuVasive has a market cap of $2.5 billion and is part of the health care sector and health services industry. Shares are up 11.34% year-to-date as of the close of trading on Monday.

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company has a P/E ratio of 54.3. Currently, there are 11 analysts who rate NuVasive a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NUVA - FREE

TheStreet Quant Ratings

rates NuVasive as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

NuVasive Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.